Daily news email for August 28, 2012 | Click here for updated news
SourceSolution News
We want to hear from you! Click here let us know how we can make this news email better.
Manage projects more efficiently. Try PlanIt free for 15 days.
Create quality questionnaires and RFPs more quickly, weight responses and manage suppliers.
Discounted advertising rates on www.sourcesolution.com for all BIOCOM members starting at $100/month
Use PlanIt as your next deal room! Click here to learn more.
|
b3c newswire
ZZ Biotech Initiates Phase 1 Study with 3K3A-APC for the Treatment of Acute Ischemic Stroke
AiCuris Promising Drugs Against Herpes Simplex (AIC316) and Human Cytomegalovirus (Letermovir, ...
CEVEC Licenses its Proprietary Human Cell Lines to Paragon Bioservices, Inc.
Cambridge Research Biochemicals Signs Deal with LI-COR Biosciences for Infrared Dye Labelled ...
2. Laupheimer Zelltage Attracts Top Scientists to Discuss Recent Advances in Biomanufacturing
|
BioSpace
Link Between Protein and Aggressive, Recurring Prostate Cancer Discovered, Johns Hopkins University Study
Rexahn Pharmaceuticals, Inc. Reports Positive Phase 2 Data for Archexin
Catalyst Pharmaceutical Partners, Inc. Raises $6 Million in Registered Direct Offering
Why Some Fats are Worse Than Others, University of New Mexico and Northwestern University Study
Forest Laboratories, Inc. Adopts Poison Pill Plan, Targets
|
BioSpace - Breaking News
Lundbeck Inc. Says Cancer Drug Approved in Canada
RBC Life Sciences, Inc. Release: Stem Cell Supplement Approved in Taiwan
Merz Pharma Group Announces the Acquisition of CUVPOSA (glycopyrrolate) Oral Solution, First and Only FDA-Approved Treatment for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions
NanoViricides, Inc. Reports that Oral Administration of FluCide Anti-Influenza Drug Candidates Caused Lung Viral Load Decrease Comparable to IV Administration and Far Superior to Oseltamivir, in a Highly Lethal Animal Model
Gene Discovery Points to New Pathways and Treatment Strategy for Amyotrophic Lateral Sclerosis (ALS), Study Funded by and Reveals
|
Biotech News - Business Wire
Renal Denervation Technology from St. Jude Medical Demonstrates Safe, Rapid and Sustained Reduction in Blood Pressure
Technologie von St. Jude Medical zur renalen Denervierung sorgt für sichere, schnelle und nachhaltige Senkung des Blutdrucks
Riassunto: La tecnologia di denervazione renale di St. Jude Medical si dimostra in grado di ridurre la pressione arteriosa in maniera sicura, rapida e sostenuta
La technologie de dénervation rénale mise au point par St. Jude Medical démontre une réduction de la pression artérielle sécurisée, rapide et durable
Samenvatting: Renale denervatie technologie St. Jude Medical geeft veilige, snelle en duurzame bloeddrukverlaging
|
Biotech News - PR Newswire
Clinical Site Services, Industry Leader in Patient Enrollment Solutions, Announces New Website
MarketsandMarkets: Global Refurbished Medical Equipments Market worth $8.45 Billion by 2017
Bacterin Secures $25 Million Financing with OrbiMed
Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Company's Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
Ingenuity Systems Named 2013 World Economic Forum Technology Pioneer
|
Biotechnology - Moreover
Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
NIH Translational Center Should Raise All Boats, BIO Says
Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
Biotechnology to be 21st-century industry: Life Tech CEO
|
Burrill Report
China Set to Increase Number of Drugs Subject to Price Controls
BMS Backs out of Crowded Hepatitis C Race
China Clones Two GM Calves
Partnering for Health
Allergan and Molecular Partners Enter $1.4 Billion Alliance
|
CenterWatch - Clinical Trials
Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
Technology companies adapt interactive video concepts for clinical trial informed consent
CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
|
